Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

G. N. Hortobagyi; S. M. Stemmer; H. A. Burris; Y. S. Yap; G. S. Sonke; S. Paluch-Shimon; M. Campone; K. Petrakova; K. L. Blackwell; E. P. Winer; W. Janni; S. Verma; P. Conte; C. L. Arteaga; D. A. Cameron; S. Mondal; F. Su; M. Miller; M. Elmeliegy; C. Germa; J. O'Shaughnessy

doi:10.1093/annonc/mdz215

Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, K. L. Blackwell, E. P. Winer, W. Janni, S. Verma, P. Conte, C. L. Arteaga, D. A. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliegy, C. GermaJ. O'Shaughnessy

Clinical Departments

Research output: Contribution to journal › Comment/debate

Abstract

Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”

Original language	English
Pages (from-to)	1842
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdz215
State	Published - Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz215

Fingerprint

Dive into the research topics of 'Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))'. Together they form a unique fingerprint.

Cite this

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., ... O'Shaughnessy, J. (2019). Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155)). Annals of Oncology, 30(11), 1842. https://doi.org/10.1093/annonc/mdz215

Hortobagyi, G. N. ; Stemmer, S. M. ; Burris, H. A. et al. / Erratum : Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155)). In: Annals of Oncology. 2019 ; Vol. 30, No. 11. pp. 1842.

@article{3989b0ee187242339ecfea164dce131e,

title = "Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))",

abstract = "Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the {\textquoteleft}Disclosure{\textquoteright} section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”",

author = "Hortobagyi, {G. N.} and Stemmer, {S. M.} and Burris, {H. A.} and Yap, {Y. S.} and Sonke, {G. S.} and S. Paluch-Shimon and M. Campone and K. Petrakova and Blackwell, {K. L.} and Winer, {E. P.} and W. Janni and S. Verma and P. Conte and Arteaga, {C. L.} and Cameron, {D. A.} and S. Mondal and F. Su and M. Miller and M. Elmeliegy and C. Germa and J. O'Shaughnessy",

note = "Publisher Copyright: {\textcopyright} 2019 THE AUTHORS",

year = "2019",

month = nov,

doi = "10.1093/annonc/mdz215",

language = "אנגלית",

volume = "30",

pages = "1842",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "11",

}

Hortobagyi, GN, Stemmer, SM, Burris, HA, Yap, YS, Sonke, GS, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, KL, Winer, EP, Janni, W, Verma, S, Conte, P, Arteaga, CL, Cameron, DA, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C & O'Shaughnessy, J 2019, 'Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))', Annals of Oncology, vol. 30, no. 11, pp. 1842. https://doi.org/10.1093/annonc/mdz215

Erratum : Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155)). / Hortobagyi, G. N.; Stemmer, S. M.; Burris, H. A. et al.

In: Annals of Oncology, Vol. 30, No. 11, 11.2019, p. 1842.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

AU - Hortobagyi, G. N.

AU - Stemmer, S. M.

AU - Burris, H. A.

AU - Yap, Y. S.

AU - Sonke, G. S.

AU - Paluch-Shimon, S.

AU - Campone, M.

AU - Petrakova, K.

AU - Blackwell, K. L.

AU - Winer, E. P.

AU - Janni, W.

AU - Verma, S.

AU - Conte, P.

AU - Arteaga, C. L.

AU - Cameron, D. A.

AU - Mondal, S.

AU - Su, F.

AU - Miller, M.

AU - Elmeliegy, M.

AU - Germa, C.

AU - O'Shaughnessy, J.

PY - 2019/11

Y1 - 2019/11

N2 - Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”

AB - Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”

UR - http://www.scopus.com/inward/record.url?scp=85077173813&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz215

DO - 10.1093/annonc/mdz215

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 31407010

AN - SCOPUS:85077173813

SN - 0923-7534

VL - 30

SP - 1842

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al. Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155)). Annals of Oncology. 2019 Nov;30(11):1842. doi: 10.1093/annonc/mdz215

Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this